Insulet Co. (NASDAQ:PODD) Shares Acquired by Mizuho Securities USA LLC

Mizuho Securities USA LLC lifted its position in Insulet Co. (NASDAQ:PODD) by 46.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,648 shares of the medical instruments supplier’s stock after purchasing an additional 2,101 shares during the quarter. Mizuho Securities USA LLC’s holdings in Insulet were worth $1,736,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Baillie Gifford & Co. grew its stake in shares of Insulet by 3.5% in the 4th quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock valued at $614,998,000 after buying an additional 79,982 shares during the period. Geode Capital Management LLC grew its position in Insulet by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock worth $403,339,000 after acquiring an additional 22,850 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Insulet by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 646,959 shares of the medical instruments supplier’s stock worth $168,902,000 after acquiring an additional 10,694 shares during the last quarter. Fisher Asset Management LLC raised its position in Insulet by 7.6% in the fourth quarter. Fisher Asset Management LLC now owns 377,694 shares of the medical instruments supplier’s stock valued at $98,605,000 after purchasing an additional 26,594 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Insulet in the fourth quarter valued at $69,433,000.

Analyst Ratings Changes

A number of brokerages recently issued reports on PODD. Wells Fargo & Company raised their price objective on Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Royal Bank of Canada assumed coverage on shares of Insulet in a research report on Thursday, March 6th. They set an “outperform” rating and a $340.00 price target for the company. JPMorgan Chase & Co. upped their price objective on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a report on Thursday, December 12th. Raymond James reiterated an “outperform” rating and issued a $328.00 target price (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Finally, StockNews.com cut Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $292.06.

Insiders Place Their Bets

In other news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.47% of the stock is owned by company insiders.

Insulet Stock Down 0.5 %

Shares of NASDAQ:PODD opened at $272.71 on Wednesday. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The firm’s 50 day moving average price is $272.27 and its 200 day moving average price is $258.19. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The stock has a market cap of $19.15 billion, a price-to-earnings ratio of 47.10, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, equities research analysts predict that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.